Law360, New York (October 13, 2006, 12:00 AM ET) -- Johnson & Johnson has asked a New Jersey district judge to prevent the launch of copycat versions of its lucrative epilepsy drug Topamax.
Johnson & Johnson’s preliminary injunction request, filed Thursday, came a month after the U.S. Food and Drug Administration cleared the way for Mylan Laboratories Inc. to sell Topiramate tablets in three dosage strengths—25 mg, 100 mg and 200 mg.
Topamax, which is covered by patents set to expire in 2008, boasts combined annual sales of approximately $1.4 billion for Johnson & Johnson....
J&J Seeks To Block Generic Topamax
To view the full article, take a free trial now.
